Treatment is recommended for all adults with chronic hepatitis B (CHB) (including pregnant women and girls and women of reproductive age) with: 1. Evidence of significant fibrosis (≥F2b) based on an APRI score of >0.5 or transient elastography value of >7 kPa or evidence of cirrhosis (F4) based on clinical criteria (or an APRI score of >1 or transient elastography value of >12.5 kPab), regardless of HBV DNA or ALT levels.